Viridian Therapeutics Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients With Chronic Thyroid Eye Disease (Ted)
維綠醫療宣佈完成治療慢性甲狀腺眼病(TED)患者的Vrdn-001的Thrive-2招募。
Viridian Therapeutics Announces Completion of Thrive-2 Enrollment for Vrdn-001 in Patients With Chronic Thyroid Eye Disease (Ted)
維綠醫療宣佈完成治療慢性甲狀腺眼病(TED)患者的Vrdn-001的Thrive-2招募。
譯文內容由第三人軟體翻譯。